Moderna vs Pfizer

Moderna was founded on the revolutionary premise that messenger RNA (mRNA) could be used to instruct human cells to create their own therapeutic proteins. For a decade, the company operated as a high-stakes, "stealth mode" biotech laboratory, burning through massive venture capital reserves to refine its lipid nanoparticle delivery systems. It spent years proving that synthetic genetic sequences could be injected into the body without triggering catastrophic immune system failures, building a massive library of intellectual property.

When the global pandemic hit, Moderna executed an unprecedented, high-speed clinical development cycle. By leveraging its pre-existing mRNA "platform" technology, the company designed, synthesized, and successfully tested its vaccine candidate in a fraction of the time traditionally required for pharmaceutical development. The firm’s rapid public listing and massive governmental partnership contracts made it the global symbol of the biotechnology race, turning the Cambridge startup into a household name.

With the extreme surge in COVID-19 vaccine demand evaporating, Moderna underwent a brutal, necessary corporate pivot. It redeployed its massive cash reserves—built during the crisis—into an aggressive, multi-front clinical research program. The company shifted its focus toward mRNA-based personalized cancer vaccines, utilizing advanced AI algorithms to scan a patient's tumor and create a bespoke genetic injection designed to train the immune system to hunt down malignant cells.

Moderna moved to prove it was not a one-hit wonder, expanding its platform into seasonal influenza, respiratory syncytial virus (RSV), and latent cytomegalovirus (CMV). By standardizing its manufacturing processes and scaling its automated production hubs, the company proved it could switch production lines between different genetic targets rapidly. This "plug-and-play" infrastructure model began to disrupt the traditional, slow-moving vaccine manufacturing processes of the old-guard pharmaceutical giants.

By mid-2026, Moderna stands as a matured, diversified biotech powerhouse with a global reach. Under the continued leadership of Stéphane Bancel, the firm has solidified its position as the leader in the genetic medicine revolution. With several high-impact therapeutic products entering late-stage commercialization, Moderna now operates as the foundational software-like engine for the next century of preventative medicine.

Charles Pfizer and his cousin Charles Erhart emigrated from Germany to New York in the 1840s and founded a fine chemicals business in Brooklyn in 1849 with $2,500 borrowed from Pfizer's father. Their first product was santonin — an antiparasitic compound used to treat intestinal worms, which were endemic among American children in the nineteenth century. They mixed it with almond-toffee flavouring to make it palatable. The product was a commercial success, establishing Pfizer as a specialty chemicals company.

During World War II, the U.S. government selected Pfizer to scale up penicillin production for Allied forces. Pfizer's fermentation expertise — developed over decades of making citric acid — proved crucial. The company developed a deep-tank fermentation process that dramatically increased penicillin yield. By June 1944, Pfizer was producing half of all penicillin made in the United States for the D-Day invasion. The wartime relationship with the U.S. government funded Pfizer's transition from chemicals to drugs.

Pfizer's researchers were conducting clinical trials on sildenafil — a drug intended to treat angina and hypertension — when male trial participants reported an unexpected side effect and were reluctant to return unused pills at the end of the trial. Pfizer pivoted the drug's development toward erectile dysfunction and launched Viagra in 1998. It was the first oral treatment for erectile dysfunction and generated $1 billion in its first year — the fastest pharmaceutical launch in history at the time. Pfizer's share price doubled.

Pfizer partnered with German biotechnology company BioNTech in 2020 to develop an mRNA vaccine against COVID-19. The vaccine was authorised for emergency use in the United Kingdom on December 2, 2020 — less than a year after the virus was first identified. Pfizer's COVID vaccine generated $36.8 billion in revenue in 2021 alone — the highest annual revenue from a single drug in pharmaceutical history. The mRNA technology used, previously unproven at scale, opened a new era in vaccine development and eventually earned BioNTech founders Uğur Şahin and Özlem Türeci the Nobel Prize in Medicine in 2023.

Pfizer reported full-year 2025 revenues of $62.6 billion — down 2% from 2024's $63.6 billion — as COVID vaccine and antiviral revenues continued to decline. Excluding COVID products, non-COVID revenue grew 6% operationally. Pfizer had delivered $4.5 billion in cost savings through 2025, acquired oncology company Seagen for $43 billion in 2023 to build a cancer drug pipeline, and acquired Metsera in November 2025. The company that had become the world's largest pharmaceutical company on the back of a pandemic vaccine was now managing the transition back to conventional pharma economics — where blockbusters took a decade to develop instead of nine months, and rarely generated $36 billion in a single year.